Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
Christian Vay(Düsseldorf University Hospital), Andreas Krieg(Düsseldorf University Hospital)
Cited by 4
Related Papers
BRAF<sup>V600E</sup> mutation: A promising target in colorectal neuroendocrine carcinoma
|International Journal of Cancer|2018|43